Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04663737 · ClinicalTrials.gov registry record · Phase 2
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
A Phase 2 study of Covid19, sponsored by Senhwa Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04663737 is a Phase 2 study of Covid19 that has completed, run by Senhwa Biosciences. The registered enrollment target is 20 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04663737, a Phase 2 study of Covid19, has completed, sponsored by Senhwa Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This single-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 20 subjects aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with moderate COVID-19. Two-arm trial comparing the SOC/supportive care alone to the SOC/supportive care with addition of Silmitasertib (allocation ratio 1:1).
Conditions Studied
Interventions
- DRUG Silmitasertib
- DRUG SOC
Study Locations (1)
Georgia
- Center for Advanced Research and Education - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2021-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04663737
The ClinicalTrials.gov registry entry for NCT04663737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (99% lower). The listed sponsor is Senhwa Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Silmitasertib is the first listed.
NCT04663737 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04663737 about?
NCT04663737 is a clinical study titled "Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19". This single-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 20 subjects aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with moderate COVID-19. Two-arm trial comparing the SOC/supporti...
What is the current status of trial NCT04663737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-11-30. Estimated completion is 2021-10-04.
What conditions does trial NCT04663737 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04663737?
The interventions under investigation include: Silmitasertib (DRUG), SOC (DRUG).
Who is sponsoring clinical trial NCT04663737?
This trial is sponsored by Senhwa Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04663737 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
Defibrotide for the Treatment of Severe COVID-19
RECRUITING · Phase 2
-
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
ACTIVE NOT RECRUITING · Phase 2
-
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.